Mannkind Corp (MNKD) 6.41 $MNKD
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
MannKind (MNKD) Stock Continues Decline Today
at The Street - Fri Apr 11, 2:25PM CDT
MannKind (MNKD) continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled...
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
One Factor Driving MannKind (MNKD) Stock Down Today
at The Street - Thu Apr 10, 1:40PM CDT
MannKind (MNKD) dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled insulin device,...
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
'Fast Money' Recap: A Rational Rally
at The Street - Thu Apr 10, 4:00AM CDT
The trading panel discussed which stocks caught a bounce and which may never make new highs.
Watch for MannKind to Potentially Pullback After Gaining 7.03% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 4:14PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.51 to a high of $7.10. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $7.01 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
MNKD July 19th Options Begin Trading
at The Street - Tue Apr 08, 10:17AM CDT
Investors in MannKind Corp saw new options become available today, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 102 days until expiration the newly...
Company News for April 08, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:06AM CDT
Companies in the News are: QCOR,MNK,GAS,MNKD,PBR
Will This Coverage Initiation Help MannKind (MNKD) Stock Today?
at The Street - Tue Apr 08, 8:20AM CDT
MannKind (MNKD) had coverage initiated on its shares with a 'market perform' rating by Brinson Patrick
MannKind Slips on Afrezza Approval Delay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:52AM CDT
The PDUFA date for MannKind's Afrezza was pushed back by the FDA by three months to Jul 15.
'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.
Petr Announces Well Online and Estimates 26,000 Barrels of Oil per Day; MannKind's Afressa Drug Decision Extended by the FDA
ACCESSWIRE - Tue Apr 08, 12:05AM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
Alcoa and Pfizer are big market movers
AP - Mon Apr 07, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
3 Huge Stocks on Traders' Radars
at The Street - Mon Apr 07, 1:11PM CDT
Here's how to trade some of the most active stocks on the market today.
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why MannKind Corp. Shares Made One Giant Leap Downward
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of MannKind , a clinical-stage...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
MannKind (MNKD) Stock Continues Decline Today
at The Street - Fri Apr 11, 2:25PM CDT
MannKind (MNKD) continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled...
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
One Factor Driving MannKind (MNKD) Stock Down Today
at The Street - Thu Apr 10, 1:40PM CDT
MannKind (MNKD) dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled insulin device,...
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. 'Fast Money' Recap: A Rational Rally
at The Street - Thu Apr 10, 4:00AM CDT
The trading panel discussed which stocks caught a bounce and which may never make new highs.
Watch for MannKind to Potentially Pullback After Gaining 7.03% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 4:14PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.51 to a high of $7.10. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $7.01 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
MNKD July 19th Options Begin Trading
at The Street - Tue Apr 08, 10:17AM CDT
Investors in MannKind Corp saw new options become available today, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 102 days until expiration the newly...
Company News for April 08, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:06AM CDT
Companies in the News are: QCOR,MNK,GAS,MNKD,PBR
Will This Coverage Initiation Help MannKind (MNKD) Stock Today?
at The Street - Tue Apr 08, 8:20AM CDT
MannKind (MNKD) had coverage initiated on its shares with a 'market perform' rating by Brinson Patrick
MannKind Slips on Afrezza Approval Delay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:52AM CDT
The PDUFA date for MannKind's Afrezza was pushed back by the FDA by three months to Jul 15.
'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.
Petr Announces Well Online and Estimates 26,000 Barrels of Oil per Day; MannKind's Afressa Drug Decision Extended by the FDA
ACCESSWIRE - Tue Apr 08, 12:05AM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
Alcoa and Pfizer are big market movers
AP - Mon Apr 07, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
3 Huge Stocks on Traders' Radars
at The Street - Mon Apr 07, 1:11PM CDT
Here's how to trade some of the most active stocks on the market today.
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 07, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why MannKind Corp. Shares Made One Giant Leap Downward
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of MannKind , a clinical-stage...
